IMRX vs RJF · $124.2M cap vs rev $15.91B
Immuneering Corp (IMRX) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
RJF (RJF) common stock.
IMRX does not have a complete income-statement cache yet.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
IMRX currently screens at market cap $124.2M. RJF currently screens at market cap $0.
Not investment advice. Open the IMRX and RJF stock pages for the full models.
Not investment advice.